Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.
Patel NC, Schwarz J, Hou XJ, Hoover DJ, Xie L, Fliri AJ, Gallaschun RJ, Lazzaro JT, Bryce DK, Hoffmann WE, Hanks AN, McGinnis D, Marr ES, Gazard JL, Hajós M, Scialis RJ, Hurst RS, Shaffer CL, Pandit J, O'Donnell CJ. Patel NC, et al. Among authors: hou xj. J Med Chem. 2013 Nov 27;56(22):9180-91. doi: 10.1021/jm401274b. Epub 2013 Nov 11. J Med Chem. 2013. PMID: 24215237
5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.
Sakya SM, Hou X, Minich ML, Rast B, Shavnya A, DeMello KM, Cheng H, Li J, Jaynes BH, Mann DW, Petras CF, Seibel SB, Haven ML. Sakya SM, et al. Bioorg Med Chem Lett. 2007 Feb 15;17(4):1067-72. doi: 10.1016/j.bmcl.2006.11.026. Epub 2006 Nov 15. Bioorg Med Chem Lett. 2007. PMID: 17126015
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S. Verhoest PR, et al. J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k. J Med Chem. 2009. PMID: 19630403
Structure-based design of novel human Pin1 inhibitors (I).
Guo C, Hou X, Dong L, Dagostino E, Greasley S, Ferre R, Marakovits J, Johnson MC, Matthews D, Mroczkowski B, Parge H, Vanarsdale T, Popoff I, Piraino J, Margosiak S, Thomson J, Los G, Murray BW. Guo C, et al. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5613-6. doi: 10.1016/j.bmcl.2009.08.034. Epub 2009 Aug 13. Bioorg Med Chem Lett. 2009. PMID: 19729306
Structure-based design of novel human Pin1 inhibitors (II).
Dong L, Marakovits J, Hou X, Guo C, Greasley S, Dagostino E, Ferre R, Johnson MC, Kraynov E, Thomson J, Pathak V, Murray BW. Dong L, et al. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. doi: 10.1016/j.bmcl.2010.02.033. Epub 2010 Feb 14. Bioorg Med Chem Lett. 2010. PMID: 20207139
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ, Kang Z, Hou X, Pandit J, Chappie TA, Humphrey JM, Marr ES, Fennell KF, Chenard LK, Fox C, Schmidt CJ, Williams RD, Chapin DS, Siuciak J, Lebel L, Menniti F, Cianfrogna J, Fonseca KR, Nelson FR, O'Connor R, MacDougall M, McDowell L, Liras S. Helal CJ, et al. J Med Chem. 2011 Jul 14;54(13):4536-47. doi: 10.1021/jm2001508. Epub 2011 Jun 8. J Med Chem. 2011. PMID: 21650160
141 results